Skip to content

Association Between Laparoscopic Removal of Endometriomas and Anti-mullerian Hormone Levels

Effects of Laparoscopic Endometrioma Removal on Anti-mullerian Hormone Levels

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02685644
Enrollment
102
Registered
2016-02-19
Start date
2016-04-30
Completion date
2018-12-31
Last updated
2016-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis, Ovarian Reserve

Keywords

endometrioma, laparoscopy, anti-mullerian hormone, ovarian reserve

Brief summary

Laparoscopic excision of endometriotic cysts is the main stream surgical intervention for treatment of endometriosis. However there is evidence that intervention may effect ovarian reserve by destruction of healthy ovarian tissue during surgery. Available evidence on the topic are contradictory and employed research methodology are diverse. There is need for an adequately powered research with proper methodology to assess actual effects of surgery.

Interventions

PROCEDURELaparoscopic removal of cysts

Women with endometrioma lesions will undergo laparoscopic removal. Cysts will be enucleated with blunt dissection of the cyst capsule and following traction, counter traction maneuver. Bipolar coagulation will be used sparsely and suturing will be the predominant choice for achieving bleeding control.

Sponsors

Ankara University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Women with endometrioma cyst(s) * Women of age under 35 years old * Women without any previous ovarian surgery

Exclusion criteria

* Combined oral contraceptive or long term GnRH (gonadotropin-releasing hormone) analog use in the preceding 3 months to enrolment * Having another cystic lesion besides endometrioma * Need for extensive bipolar coagulation during surgery * Any anatomical problem preventing evaluation of ovaries with high-resolution ultrasound * Postoperative pathology excluding endometrioma

Design outcomes

Primary

MeasureTime frameDescription
Anti-Mullerian hormone levels1 yearAMH (anti-mullerian hormone) levels will be measured before surgery and during various time points up to 1 year after the surgery

Contacts

Primary ContactErkan Kalafat
ekalafat@ankara.edu.tr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026